fbpx

Blog

PSA and NAPSA renew agreement for 2024/25

3 August 2024

The Pharmaceutical Society of Australia (PSA) and the National Australian Pharmacy Students’ Association (NAPSA) have renewed their longstanding partnership to further support for pharmacy students at pharmacy schools across Australia.

 

The renewed Memorandum of Understanding (MOU), signed at the PSA24 National Conference, supports key NAPSA initiatives including the National Pharmacy Student Survey and the NAPSA Congress, and ensures that students are supported with professional development and further education opportunities throughout their studies.

 

PSA National President Associate Professor Fei Sim FPS reaffirmed PSA’s commitment to supporting pharmacy students.

 

“PSA has a long and proud history of supporting pharmacy students, which we are proud to continue.

 

“Students are the future of our profession, and it is our responsibility to support them in every possible way. Through this ongoing collaboration with NAPSA, we are not only investing in their education but also in the future of our profession.”

 

“This agreement not only strengthens our commitment to the development of future pharmacists but also reinforces our dedication to advancing the pharmacy profession as a whole. We look forward to continuing our close partnership with NAPSA and to seeing the positive impact this will have on pharmacy students across Australia.”

 

NAPSA President Sebastian Harper welcomed the renewed agreement.

 

“PSA is the peak body representing all 38,000 pharmacists in Australia across areas of practice.

 

The renewed agreement between the NAPSA and PSA exemplifies our organisations’ commitment to advancing the interests of pharmacy students.

 

“As the industry takes on new opportunities and challenges in the advancement of full scope, there has never been a better time to be a member of your representative bodies.”

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA24: Locum Pharmacist of the Year

3 August 2024

Locumate.ai Co-founder Kavita Nadan, Locum Pharmacist of the Year Esther Staal, Associate Professor Fei Sim.
Photo: Josh Woning

The Pharmaceutical Society of Australia (PSA) has today named Tasmanian pharmacist Esther Staal as the 2024 PSA Locumate.ai Locum Pharmacist of the Year, awarded at PSA24’s opening plenary this morning (Saturday 3 August).

 

Ms Staal is an empowered locum pharmacist focused on continued learning and professional development to improve practice. She is passionate about her growth as a health professional and reflects on her practise and the patients she meetings across different communities, from the goldfields of Kalgoorlie to the retirees in Vasse.

 

Esther quickly embeds herself in all aspects of being a locum, quickly building mutual rapport with pharmacists and general practitioners and embracing the active rural and regional communities she’s practising in. Her energy and willingness to champion a high standard pharmacy practice makes her well adored in each community she practises in.

 

Presenting the award, PSA National President Associate Professor Fei Sim FPS congratulated Ms Staal.

 

“I’m proud to award Esther Staal with the PSA Locumate Locum Pharmacist of the Year Award, acknowledging the vital work of locum pharmacists around the country.

 

“Anyone who has practised in a pharmacy, especially in a rural or regional area, knows just how important locum pharmacists are in keeping healthcare accessible to our communities. There are unique challenges for locum pharmacists, but those like Esther take it all in their stride.

 

“I sincerely thank Esther and all locum pharmacists around Australia for all that they do. The role of a locum is often overlooked, however it is important to recognise that they are a critical part of the foundation of a complete team.”

 

Locumate.ai. Co-Founder and Director Kavita Nadan also congratulated Ms Staal.

 

“On behalf of Locumate.ai, we extend our heartfelt congratulations to Esther Staal.

 

“Esther’s passion and commitment to our profession are evident in her exceptional work as a dedicated locum pharmacist. Her unwavering care and attention to her patients make her a valuable asset to our communities.

 

“Esther is an exemplary locum pharmacist, and we at Locumate.ai are proud of her efforts in promoting and highlighting the incredible contributions locum pharmacists make.”

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA24: Intern Pharmacist of the Year

3 August 2024

Associate Professor Fei Sim, Intern of the Year James Oh, MIMS Australia CEO Robert Best
Photo: Josh Woning

The Pharmaceutical Society of Australia (PSA) has today named Bowen-based pharmacist James Oh as the 2024 PSA MIMS Intern Pharmacist of the Year, awarded at PSA24’s opening plenary this morning (Saturday 3 August).

 

Mr Oh graduated from James Cook University in 2023, receiving the Professor James Dare Graduate of the Year award recognising both academic success as well as excellence in leadership, ethics and community engagement.

 

Throughout his intern year, Mr Oh has seen first-hand the impact that accessible pharmacists have on his community in Bowen, Queensland. James takes a lead role in his community practice, demonstrating a strong appetite for areas of practice that are forward-facing and impactful on patient outcomes, with a particular focus on Meds Checks and immunisation as opportunities to optimise patient care.

 

Mr Oh’s positive attitude and leadership qualities endear him to the local community, forming strong relationships with both patients and his peers. Outside the pharmacy, Mr Oh works with undergraduate students at James Cook University as a role model and mentor, actively participating with student organisation NAPSA and the PSA.

 

Presenting the award, PSA National President Associate Professor Fei Sim FPS congratulated Mr Oh.

 

“Intern and early career pharmacists like James Oh show us that the future of our profession is very bright.”

 

“It’s great to see pharmacists like James going to regional and rural Australia, taking challenges head-on and embracing all of the opportunities that are coming our way.

 

“Congratulations James – we at PSA cannot wait to continue supporting you throughout the rest of your pharmacy career, wherever that takes you,” Associate Professor Sim concluded.

 

MIMS CEO Robert Best also congratulated Mr Oh, reaffirming MIMS commitment to supporting the next generation of pharmacists.

“Last year, in 2023 MIMS celebrated our 60th Anniversary as the most trusted provider of drug and medicines information across the Australian healthcare industry,” Mr Best said.

“We see the pharmacy profession as the most important and pivotal part of our medicines ecosystem when dealing with consumers and patients, so, as we approach the halfway point of this 2024 Olympic year, we will continue to acknowledge the Gold Medal role that pharmacists and their interns play with respects to advising, educating and dispensing medicines across Australia.

“For more than 60 years, MIMS has been the most trusted provider of drug and medicines information across the Australian healthcare industry. We will continue to provide the Pharmacy industry, from interns through to Chief Pharmacists, with the most of up-to-date drug and medicines information available at the point of care,” Mr Best concluded.

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA24: New cohort of PSA Fellows recognised for contributions

3 August 2024

The Pharmaceutical Society of Australia (PSA) is pleased to present 26 PSA Fellowships this weekend at PSA24, recognising the significant contributions of members to both the profession and PSA.

 

Among the new Fellows is Assistant Minister for Mental Health and Suicide Prevention and

Assistant Minister for Rural and Regional Health the Honourable Emma McBride MP – the only pharmacist currently serving in the Australian Parliament.

 

Associate Professor Fei Sim FPS welcomed the new Fellows to PSA’s growing community of pharmacy leaders.

 

“Each of these pharmacists have made significant contributions to pharmacy and patient care, exemplifying the passion and dedication of our profession.

 

“Fellowships of PSA are a prominent acknowledgement of those who have provided an outstanding contribution to PSA or the profession for an extended period of time.

 

“As a profession we thank them for their ongoing service and dedication to improving pharmacy practice.”

 

The following pharmacists have been elevated to Fellows of the Pharmaceutical Society of Australia:

  • Ms Bronwyn Clark (Australian Capital Territory)
  • Adjunct Professor John McEwen (Australian Capital Territory)
  • Ms Lyn Todd (Australian Capital Territory)
  • Ms Caroline Diamantis (New South Wales)
  • Dr Cherie Lucas (New South Wales)
  • The Honourable Emma McBride MP (New South Wales)
  • Dr Jonathan Penm (New South Wales)
  • Dr Sarah Dineen-Griffin (New South Wales)
  • Mr Gilbert Yeates (Queensland)
  • Dr Julie Stokes (Queensland)
  • Ms Dianne Brown (Tasmania)
  • Ms Katie Hayes (Tasmania)
  • Mr Mark Kirschbaum (Tasmania)
  • Ms Dimi Hoppe (Victoria)
  • Mr Joe Brizzi (Victoria)
  • Ms Kay Dunkley (Victoria)
  • Professor Simon Bell (Victoria)
  • Ms Stefanie Johnston (Victoria)
  • Dr Amanda Cross (Victoria)
  • Ms Brooke Shelly (Victoria)
  • Ms Deborah Hawthorne (Victoria)
  • Ms Atinuke (Tinu) Abraham (Victoria)
  • Mr Joon Soo Park (Western Australia)

 

The following pharmacists have been elevated to Life Fellows of the Pharmaceutical Society of Australia:

  • Ms Helen Howarth (Tasmania)
  • Mr Ian Huett (Tasmania)
  • Ms Jocelyn Watson OAM (Tasmania)

 

Both Professor Faye McMillan and Professor Arthur Christopoulos were also recognised at last night’s event after receiving PSA Fellowships in 2023.

 

PSA congratulates each of the above pharmacists on their achievements and sustained contributions to the pharmacy profession.

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA24: Launch of Opioid Toolkit to promote safer medicine use

2 August 2024

 

Professor Suzanne Nielsen at PSA24 – ICC, Sydney, 2-4 August 2024.
Photo: Josh Woning

 

Monash University has today launched its new online Opioid Safety Toolkit for consumers, inviting delegates attending PSA’s National Conference, PSA24 so pharmacists can gain early access to prepare for its public release in late August.

 

The Toolkit, developed in partnership with the Pharmaceutical Society of Australia (PSA) and PainAustralia, supports consumers who are prescribed opioids and contains advice on safer opioid use as well as guidance on how to develop an opioid safety plan in case of an adverse reaction.

Crucially, the Opioid Toolkit raises awareness among consumers that naloxone is available at no cost from Australian community pharmacies. It is estimated that less than 2% of patients at risk of a prescription opioid overdose received naloxone. This work aims to make opioid safety information and naloxone more readily available to all people who may benefit from it.

 

The Opioid Safety Toolkit is funded by the Department of Health and Aged Care and was developed by pharmacists, consumers and other health professionals.

 

Monash University Lead Investigator Professor Suzanne Nielsen said that the Toolkit leverages more than a decade of research into safer use of prescription opioids.

 

“This resource provides a new tool for pharmacists to use when providing information on the use of opioids. It can be provided to any person prescribed opioids, whether new or ongoing, and can be accessed at any time convenient to the patient.

 

“It will help pharmacists to deliver effective patient education in a non-judgemental manner that the patient can access whenever a question arises.”

 

PSA National President Associate Professor Fei Sim FPS welcomed the launch of the Toolkit as an additional resource for consumers.

 

“Pharmacists are well placed to take a leading role in reducing opioid harm in Australia, empowering consumers with the right information and guidance to support the safer use of opioids. All Australian pharmacists will be able to use the toolkit to have open conversations with patients using opioids, and increase uptake of naloxone as a harm reduction tool.

 

“I strongly encourage all pharmacists, whether practising in a community pharmacy setting, hospital or in other areas of specialisation, to access the Toolkit resources and promote their uptake with consumers.”​

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Vision for Pharmacists in 2030 launched at PSA24

2 August 2024

 

On the first day of its national conference PSA24, the Pharmaceutical Society of Australia (PSA) has launched its flagship vision for the future of Australian pharmacy practice, Pharmacists in 2030, alongside Federal Health Minister the Hon. Mark Butler MP.

Pharmacists in 2030 is an evolution of PSA’s vision for the future of the pharmacy profession, and the steps that need to be taken to get there. Compared to its predecessor, Pharmacists in 2030 has an increased focus on equity, medicines stewardship and pharmacist wellbeing, while maintaining focus on medicine safety, expanding scope of practice and integration of pharmacists into collaborative care teams.

The vision is a culmination of deep consultation with pharmacists, consumers and other health stakeholders. Informed by consumers across 14 in-depth focus groups, Pharmacists in 2030 describes how the care pharmacists provide will change over the next 6 years’ through the lens of both pharmacists and patients.

Pharmacists in 2030 articulates six key actions to realise this vision:

  • Medicine safety – empowering and supporting pharmacists to reduce risks and minimise harm by advancing medicine safety in practice
  • Medicines stewardship – supporting pharmacists to actively lead and influence effective and judicious medicine use
  • Access to care – providing all consumers greater access to care by increasing and leveraging the accessibility of pharmacists to address unmet health needs
  • Equity – supporting pharmacists to meet the unique needs of vulnerable individuals and priority populations to address the disparity of health status through the provision of appropriate and responsive care
  • Workforce development – equipping and growing the pharmacist workforce to address existing and emerging health challenges
  • Sustainability – driving practice changes that increase the sustainability of the pharmacist workforce, increase social contribution and limit environmental impact

 

These actions empower pharmacists to embrace their full potential to not only meet Australia’s surging health needs over the next six years, but also to build capacity to address health challenges beyond 2030.

PSA National President Associate Professor Fei Sim FPS said that today’s launch built on the growing momentum behind the profession.

“In launching Pharmacists in 2030, we are progressing PSA’s vision for the future of pharmacy practice in Australia,” A/Prof Sim said.

“Our profession has evolved significantly, and continues to evolve, to meet the increasingly complex health needs of Australians, our aging population and overstretched health system. Our communities need us to continue down this path, they need all pharmacists doing more to support safe use of medicines and greater access to care when and where they need it.

Pharmacists in 2030 leverages the appetite for change in our health system, driven by patient needs, and provides a roadmap for the next 6 years on how pharmacists’ full potential can be realised. It helps government, policymakers and funders understand our value and potential.

 

Pharmacists in 2030 challenges the entire health ecosystem to collaboratively drive pharmacy practice to the next level, including policymakers, patients and consumers.

“We know that regulatory change alone is not enough. We need to address the cultural and system factors which hold our profession back and importantly, we cannot continue expecting pharmacists to do more with less.

“Our goal is getting to a point where practice is more efficient, relieving unnecessary administrative burden so that pharmacists can focus on delivering the care that patients need.

“Each one of us, in all areas of practice and specialisations have a role to play in realising this vision by 2030. The daily practice of pharmacists in direct patient-care roles will see the most evolution in their daily roles, enabled by pharmacists practising in non-patient facing roles, including academia, management and leadership.”

Associate Professor Sim also thanked all the pharmacists that participated in consultation on Pharmacists in 2030.

Pharmacists in 2030 is for the future of every pharmacist,” she said.

“Whether responding to the official consultation, speaking to our teams around the country about the future, or contributing to our social media pages – the collective wisdom of our profession and health consumers has built the path forward for all pharmacists.

“I thank Minister Butler for officially launching Pharmacists in 2030 at PSA24, alongside the passionate pharmacists and consumers who shaped it,” Associate Professor Sim concluded.

 

Pharmacists in 2030 is available to pharmacists and the public at www.psa.org.au/pharmacists_in_2030  

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA24: South Australian pharmacist’s lifetime of service honoured on national stage

2 August 2024

The Pharmaceutical Society of Australia (PSA) has today recognised Adelaide pharmacist Peter Halstead with the 2024 PSA Symbion Lifetime Achievement Award presented at PSA’s national conference in Sydney.

 

Over his 40-year long career, Peter Halstead has made a sustained contribution to the pharmacy profession and associated organisations, dedicating himself to developing and advancing Australian pharmacy practice. Through these activities, Peter has made a significant contribution to patient care. He has been an advisor, mentor and friend to many members of our profession and epitomises the values of the Pharmaceutical Society of Australia.

 

After graduating in 1980, Mr Halstead practised as a community pharmacist and was instrumental in developing new areas of practice and became a pharmacist adviser to the Department of Veterans Affairs, the Drug and Alcohol Services and The Family Planning Unit at SHINE SA.

 

In 1996, Peter joined the School of Pharmacy as a research fellow involved with Professor Andy Gilbert and others in the development of new pharmacist roles, particularly in Aged Care services.

 

In the period 2000 to 2001, Peter was the Education Officer of the Pharmacy Board of South Australia and from 2001 to 2010 he was the Registrar of the Board, a position which he held with distinction until the formation of the National Pharmacy Board. During his tenure, Peter developed and implemented systems and procedures that allowed the formal assessment of the competency of recent graduates and others seeking registration as pharmacists in South Australia.

 

Peter was a Director of the Australian Pharmacy Council (APC) from 1996 to 2010 and since 2010 has been the Senior Pharmacist for the APC involved in the development of assessment processes for intern pharmacists as well as pharmacists from overseas seeking registration with the National Pharmacy Board. He actively supported many overseas pharmacists who were going through the formal process of seeking registration and became a mentor to many.

 

Peter was appointed as the General Manager of the Pharmacy Regulation Authority, South Australia (PRASA) in 2010, a position he held for 12 years until his recent retirement. During this period, he continued to engage with the Pharmacy Board of Australia on many issues affecting Australian pharmacy practice.

 

Presenting the award, PSA National President Associate Professor Fei Sim said: “Peter Halstead is a most deserving recipient of the PSA Lifetime Achievement Award.”

 

“Over a career spanning more than 40 years, Mr Halstead has made enormous and sustained contributions to the pharmacy profession, dedicating himself to developing and advancing Australian pharmacy practice. His work continues to influence our profession every day.

 

“On behalf of the pharmacy profession, I congratulate Mr Halstead on receiving the 2024 PSA Symbion Lifetime Achievement Award.”

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

The Pharmaceutical Society of Australia is the only national peak body that represents all of Australia’s pharmacists across all practice settings. We want every Australian to have access to the best healthcare, and this must include optimising access to pharmacists’ knowledge and medicines expertise at the forefront of our healthcare system.

PSA24: Victorian researcher awarded top pharmacy honour

2 August 2024

The Pharmaceutical Society of Australia (PSA) has today named researcher and Melbourne-based pharmacist Dr Amy Page as the national PSA Symbion Pharmacist of the Year.

 

Presented by National President Associate Professor Fei Sim at PSA’s national conference in Sydney, Dr Page was acknowledged for her extensive work with pharmacists, students and other healthcare professionals.

 

Dr Amy Page is the President of PSA’s Victorian branch, a leading pharmacy researcher, academic and practising pharmacist. She is driven by her dedication to elevating pharmacy practice both nationally and internationally for a sustained impact on practice and medicines safety to improve the wellbeing of all Australians.

 

In 2018, Dr Page led work with the Pharmacy Board of Australia and the Australian Health Practitioner Regulation Agency to investigate the regulatory environment for pharmacist prescribing, resulting in a statement that confirmed the ability for pharmacists to prescribe within current regulation. This work has directly resulted in pharmacist prescribing pilots for urinary tract infections, oral contraception, skin conditions and travel health – improving the accessibility of care to millions of Australians.

 

Through her role as a Senior Lecturer at the University of Western Australia Dr Page is also passing on her passion and dedication to the next generation of pharmacists.

 

Dr Page contributes nationally to advancing pharmacy practice through her involvement in research, policy and regulation. She has brought about significant and lasting change in pharmacist prescribing and pharmacy practice standards through her research and her sustained engagement with professional organisations and regulators. Amy is established as a world leader in her research field of medicines safety and pharmacy practice. She’s been invited to give presentations internationally, including in China and the United Kingdom.

 

Her research has been used to justify policy changes (such as the National Aged Care Quality Indicators) and to assess the impact of policy change (e.g. polypharmacy prevalence). Her work has influenced guideline development internationally and beyond her field including being recommended by NPS MedicineWise, the British Geriatric Society and the New Zealand Safety and Quality Commission.

 

Beyond the pharmacy profession, Dr Page has also progressed non-medical prescribing within other disciplines nationally. As a leading Australian expert, she continues to work with the Physiotherapy Board and Optometry Australia on their journeys toward prescribing.

 

Dr Page has achieved this while continuing to practice clinically, currently working both in community pharmacy and undertaking medicines reviews.

 

PSA National President Associate Professor Fei Sim congratulated Dr Page, saying: “PSA is proud to name Dr Amy Page as Pharmacist of the Year, recognising not only her clinical leadership but also her commitment to raising the profile of the profession.”

 

“Dr Page has dedicated her career to leading our profession, whether in her role as a Senior Lecturer at the University of Western Australia, as the inaugural Director of the Centre for Optimisation of Medicines, or serving as part of the Pharmacy Board of Australia.

 

“Dr Page is a deserving recipient of the 2024 Pharmacist of the Year title, embodying what it means to be a pharmacist every day of her career to date.

 

“On behalf of the pharmacy profession, I congratulate Dr Page on being named the 2024 PSA Symbion Pharmacist of the Year.”

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

PSA24: Nation’s leading pharmacists awarded

2 August 2024

PSA24 – ICC, Sydney, 2-4 August 2024.
Photo: Josh Woning

Three outstanding Australian pharmacists have been recognised today by the national peak body for pharmacists, the Pharmaceutical Society of Australia (PSA). The 2024 Excellence Awards were presented alongside award sponsor Symbion at PSA’s national conference, PSA24, in Sydney.

 

The recipients of the 2024 PSA Symbion Excellence Awards are:

  • Dr Amy Page FPS, Pharmacist of the Year
  • Peter Halstead FPS, Lifetime Achievement Award

 

Presenting the awards, PSA National President Associate Professor Fei Sim FPS congratulated the recipients.

 

“The PSA Excellence Awards acknowledge the pharmacists who go above and beyond, those who are involved in innovative practice, those who are striving to raise practice standards, and those who, through their professionalism, provide a model of practice which others strive to emulate,” Associate Professor Sim said.

 

“PSA congratulates Dr Amy Page as Pharmacist of the Year, recognising her clinical leadership in quality use of medicines, and her commitment and consistent volunteer work to raise the profile of the profession. Dr Page has dedicated her career to leading our profession, whether in her role as an academic at the University of Western Australia, as the inaugural Director of the Centre for Optimisation of Medicines, or serving on the Pharmacy Board of Australia. Dr Page is a deserving recipient of the 2024 Pharmacist of the Year title, embodying what it means to be a pharmacist every day of her career to date.

 

“Over a career spanning more than 40 years, Peter Halstead has made enormous and sustained contributions to the pharmacy profession, dedicating himself to developing and advancing Australian pharmacy practice. His work continues to influence our profession every day.

 

“On behalf of PSA and the pharmacy profession, congratulations to Dr Page, and Mr Halstead,” Associate Professor Sim concluded.

 

Symbion CEO Brett Barons also congratulated the award winners.

“Pharmacists are the backbone of Australia’s healthcare system and Symbion is proud to sponsor the PSA Excellence Awards for a 20th year and help celebrate those pharmacists making their mark on the industry,” Mr Barons said.

“On behalf of Symbion, I congratulate this year’s winners on their outstanding achievements and deserved recognition for their commitment to deliver the highest level of care to their communities.”

 

 

Media notes

 

Dr Amy Page is the Victorian President of the PSA and a practicing pharmacist with an impressive research output and sustained engagement with policy and regulation. She has had a sustained engagement with policy and regulation to progress non-medical prescribing and to improve the development and use of practice-based resources for the profession.

 

Dr Page was invited to lead the Pharmacy Board of Australia work on pharmacist prescribing in 2018. This work was the first time an AHPRA board had progressed non-medical prescribing since the formation of the National Registration and Accreditation Scheme in 2010. She led the

consultation process undertaking extensive stakeholder engagement and producing written reports. This work resulted in a statement that no regulatory barrier existed for pharmacists to prescribe. As a direct result of this work, pharmacists prescribing has been introduced in multiple Australian states.

 

In 2023, pharmacist prescribing was launched in Victorian community pharmacies for certain conditions. As Victorian state PSA president, her substantial contribution to the working groups for the Victorian prescribing pilot informed its implementation. This has now led to community pharmacy prescribing pilots for urinary tract infections, oral contraception, skin conditions and travel health.

 

In her role on the Pharmacy Board of Australia, she initiated the development of the first Australian accreditation standards for non-medical prescribing. The Pharmacy Board appointed the Australian Pharmacy Council to develop Prescribing Standards for the profession. In recognition of her leadership, the Pharmacy Board appointed Amy as their representative to guide the development of these new national accreditation standards. Simultaneously, Amy also sat on the Expert Advisory Group to develop the new APC Medication Management Review and Aged Care standards.

 

Broadening her impact beyond the profession, she has progressed non-medical prescribing nationally. As a recognised expert in non-medical prescribing, she was involved in developing the NPS Prescribing Competencies. Over the past two years, she has been contributing to the Physiotherapy Board’s journey towards prescribing, thus broadening the impact of her work beyond the profession. She was one of four invited experts who presented to almost 1000 physiotherapists who attended their prescribing forum, work that is ongoing towards achieving autonomous prescribing. She is one of only two pharmacists on the Physiotherapy Prescribing Working Group convened jointly by the Australian Physiotherapy Association and the Physiotherapy Board of Australia. Further broadening her impact, Optometry Australia contracted her to write their Quality Use of Medicines guidelines in preparation for an anticipated expansion in their scope of prescribing to include oral medicines.

 

Dr Page contributes nationally to advancing pharmacy practice through her involvement in research, policy and regulation. She has brought about significant and lasting change in pharmacist prescribing and pharmacy practice standards through her research and her sustained engagement with professional organisations and regulators. Amy is established as a world leader in her research field of medicines safety and pharmacy practice. She’s been invited to give presentations internationally, including in China and the United Kingdom.

 

Her research has been used to justify policy changes (such as the National Aged Care Quality Indicators) and to assess the impact of policy change (e.g. polypharmacy prevalence). Her work has influenced guideline development internationally and beyond her field including being recommended by NPS MedicineWise, British Geriatric Society and NZ Safety and Quality Commission.

 

Dr Page has achieved this while continuing to practice clinically, currently working both in community pharmacy and undertaking medicines reviews.

Dr Page is awarded the 2024 PSA Pharmacist of the Year award.

 

 

Over his 40-year long career, Peter Halstead has made a sustained contribution to the pharmacy profession and associated organisations, dedicating himself to developing and advancing Australian pharmacy practice. Through these activities, Peter has made a significant contribution to patient care. He has been an advisor, mentor and friend to many members of our profession and epitomises the values of the Pharmaceutical Society of Australia.

 

After graduating in 1980, Mr Halstead worked as a community pharmacist and was instrumental in developing new areas of practice and became a pharmacist adviser to the Department of Veterans Affairs, the Drug and Alcohol Services and The Family Planning Unit at SHINE SA.

 

In 1996, Peter joined the School of Pharmacy as a research fellow involved with Professor Andy Gilbert and others in the development of new pharmacist roles, particularly in the area of Aged Care services.

 

In the period 2000 to 2001, Peter was the Education Officer of the Pharmacy Board of South Australia and from 2001 to 2010 he was the Registrar of the Board, a position which he held with distinction until the formation of the National Pharmacy Board. During his tenure, Peter developed and implemented systems and procedures that allowed the formal assessment of the competency of recent graduates and others seeking registration as pharmacists in South Australia.

 

Peter was a Director of the Australian Pharmacy Council (APC) from 1996 to 2010 and since 2010 has been the Senior Pharmacist for the APC involved in the development of assessment processes for intern pharmacists as well as pharmacists from overseas seeking registration with the National Pharmacy Board. He actively supported many overseas pharmacists who were going through the formal process of seeking registration and became a mentor to many.

 

Peter was appointed as the General Manager of the Pharmacy Regulation Authority, South Australia (PRASA) in 2010, a position he held for 12 years until his recent retirement. During this period, he continued to engage with the Pharmacy Board of Australia on many issues affecting Australian pharmacy practice.

 

Mr Halstead is awarded the 2024 PSA Lifetime Achievement award.

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.a

TRANSCRIPT: PSA National President opening address at PSA24

2 August 2024

 

Thank you, Aunty Joan Bell, for the beautiful and warm Welcome to Country and for sharing her story with us.

 

I too, would like to acknowledge the traditional custodians of the land we meet on today, the Gadigal People of the Eora Nation.

 

In the spirit of reconciliation, PSA acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present. I personally extend that respect to all Aboriginal and Torres Strait Islander peoples today.

 

Good morning PSA.

 

In preparing today’s opening, I reflected on our journey in the past 2 years.

 

Two years ago, I delivered my first opening plenary at PSA22– I was exhilarated, nervous, but motivated.

 

This time last year, as I delivered my second opening plenary – I, together with the profession that I love dearly, we were solemn. I would say melancholy at times, but we were cautiously hopeful. We were hopeful because of our belief in our profession, in our community we serve, in our resilience, in our impact and our irreplaceable role.

 

Today 12 months later, I stand here, together with you PSA members, my Board, Branch Presidents, Branch Committees and the amazing PSA Team, and the 3 words I’ve chosen are optimistic, assured, and focused.

 

On behalf of our profession, I am grateful to our government. I want to acknowledge and thank our Federal Minister for Health and Aged Care Minister Mark Butler who will be joining us this afternoon, and Assistant Minister Emma McBride, who is present with us today.

 

After 15 months of uncertainty, our profession welcomed the signing of the 8th Community Pharmacy Agreement and Strategic Agreement. I want to acknowledge the work of the Pharmacy Guild of Australia, their National President Prof Trent Twomey and his team, some of them are with us today. The 8CPA has delivered the much-needed certainty our community pharmacy sector needed.

 

Also on behalf of the profession, I am incredible proud of PSA’s achievement and signing of the first, historic, Strategic Agreement on Pharmacist Professional Practice is monumental.

 

For the first time, the Strategic Agreement articulates the Australian Government’s commitment to support the highest standard of professionalism in pharmacy. Through this Agreement, for the very first time our profession as a whole, received formal recognition and support for our professional practice – recognising that we are an essential part of the healthcare team, and importantly the respect that pharmacists deserve as clinicians in this health care system.

 

For the first time, there is shared vision between our profession and the Commonwealth Government to continue to expand the range of primary healthcare services pharmacists provide, regardless of areas of practice.

 

The Strategic Agreement gives recognition to pharmacists’ expertise and contribution to quality use of medicines and medicine safety.

 

It gives confidence to our patients, our funders and our health system. It gives our profession the framework for standards and guidelines moving forward, as we continue to navigate through practice and health landscape changes.

 

Whilst these are all positive news, as I mentioned earlier, we need to remain focused. The work is not done. Whilst there is ongoing funding for HMRs and RMMRs, and that the Aged Care On-site Pharmacist Program has now formally commenced, the work and viability of our credentialed pharmacist workforce will not be forgotten.

 

Regardless of areas of practice, I truly have never felt so positive about the opportunity for pharmacists to reach our full potential. These opportunities are driven by real needs of our patients and our health system.

 

The current Scope of Practice Review is our opportunity – it is what I would describe as a once-in-a-career lifetime opportunity to challenge the very foundation of health system administration – to achieve equity for all health professionals, including pharmacists, in terms of regulations, funding policy and workforce development. Whether it is through our submissions, in formally representing pharmacists on the Expert Advisory Committee, in attending workshops – members can be assured that PSA is making strong representation.

 

What we want to see is:

 

Removing of unnecessary red tapes, empowering pharmacists to achieve our full and top of scope in being stewards of medicines safety, to have responsibility for the outcomes of and accountability for the outcomes of medicine use, and to truly be the first port of call for primary healthcare.

 

Through national harmonisation of states and territories legislation and regulations – patients across the country should be able to access the same level of healthcare access, not just in those areas where their postcodes are in the 4000’s.

 

Direct referral to pathology – if you’re undertaking a medication review, you should be able to order and access pathology tests which are critical to making meaningful recommendations, consistent with treatment guidelines.

 

Whether you are prescribing or undertaking medication management reviews, it makes no sense you can’t send a patient for Medicare funded blood tests relevant to that service. And it certainly does not make sense that you can’t contribute clinical notes to a patient’s health record.

 

There should be consistent funding policies – We should have access to the MBS for consultation, and should be able to prescribe medicines within our scope under the PBS.

 

Same job same pay – We should get paid the same for providing a vaccination as any other immunisers.

 

Our workforce should be supported to be integrated within multidisciplinary care teams in a meaningful way – in terms of roles, recognition and remuneration.

 

We can do more, but we must also be supported and remunerated to do more. We cannot keep adding more work, we cannot keep expecting pharmacists to do more with less.

 

We need technology to be a facilitator, not a barrier.

 

We need the teams around us to take on more technical work so that we can focus on more cognitive work.

 

We need regulation that is up to date, that supports safer, more efficient care, not get in the way of it.

 

We need to spend more time using the full extent of our skills and expertise to provide patient care.

 

These are sensible and very long overdue asks. Once the report is finalised, we urge the government to start implementing the Review’s recommendations immediately.

 

Executed well, this will dramatically simplify our unnecessarily complicated health system and help all health professionals, including pharmacists, increase their capacity to provide care.

 

I want to take this opportunity to thank and acknowledge representatives from the Department of Health and Aged Care for their work, and PSA appreciates your work and we look forward to continuing our collaborative effort to achieve this aim.

 

Australians deserve a health system which functions better than it does now.

 

This afternoon, I hope you will join me in attending Minister Mark Butler’s address.

 

Today Minister Butler will officially launch our vision for the future of pharmacy practice in Australia – Pharmacists in 2030.

 

Pharmacists in 2030 leverages the real appetite for change in our health system, driven by patient needs, and importantly provides a roadmap for the next 6 years on how pharmacists’ full potential can be realised.

 

It helps government, policymakers and funders understand our value and potential.

 

While I won’t spoil its contents, I will say a huge thank you to every one of you, our members, our elected officials, PSA Team, the Australian Pharmacy Leaders Forum member organisations who are also here today, and our consumers, who contributed to this document.

 

Martin Luther King Jr once said: “The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy.”

 

Pharmacists – We know it hasn’t been easy. We know practice is getting harder and more complex. We know it can be overwhelming. But, we must keep going.

 

As we continue to evolve our profession to meet healthcare needs of Australians, I see the next 5 years as critical in the development and preparation of our workforce.

 

PSA’s work will focus on building a pharmacy workforce which has the capability and capacity to meet the health needs of Australians into the future.

 

No matter what, PSA is pharmacy, and PSA is here throughout our pharmacy career, and we should never feel alone. We are here, we are all here to be your career partner to navigate the future together.

 

It is now time to welcome our Assistant Minister for Mental Health and Suicide Prevention, and Assistant Minister for Rural and Regional Health, Emma McBride, to the stage.

 

 

 

Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au